When will niraparibabiraterone tablets be released on the market?

Niraparibabiraterone Tablets (Akeega) is a new oral compound targeted drug for the treatment of prostate cancer. It was developed by Johnson & Johnson (Janssen) and combines two core ingredients - the PARP inhibitor nirapar Niraparib and the androgen synthesis inhibitor Abiraterone are used to treat BRCA gene mutation-related castration-resistant prostate cancer (mCRPC). The comparison of the approval time of this innovative drug in multiple regions around the world clearly demonstrates its rapid deployment in the international market.

Akeega was first approved by the European Medicines Agency (EMA) on April 19, 2023, becoming the first combined PARP inhibition and androgen suppression preparation in Europe. Subsequently, on August 11, 2023, the U.S. Food and Drug Administration (FDA) also officially approved its marketing for the treatment of patients with advanced prostate cancer with BRCA1/2 mutation background. This marked the gradual establishment of Akeega’s global status as a dual-pathway targeted drug. In the Chinese market, October 21, 2024. Johnson & Johnson officially announced that Akeega has received official marketing approval from the National Medical Products Administration (NMPA) of China. As a compound preparation, it is given the trade name "Akeega®" in China and has been included in the precision treatment of metastatic castration-resistant prostate cancer carrying BRCA mutations.

With the rapid popularization of the concept of precision medicine,The launch of Akeega is regarded as an upgrade in China's prostate cancer treatment options, providing a more personalized and targeted treatment option for a type of patients with specific genetic characteristics. Its dual mechanism not only improves the drug's comprehensive tumor suppression ability, but also lays the foundation for future combination treatment models. Therefore, Akeega quickly completed the launch process in Europe, the United States and China in just one year, setting a model for global drug registration efficiency and innovation path optimization.

Reference materials:https://www.drugs.com/akeega.html